Refine Pipeline

Use the filters below to refine your results

Phase

Pre-clinical
Phase One
Phase Two
Phase Three
Available to Patients

Therapeutic Approach

Binding gluten so it’s not absorbed
Breaking down gluten using enzymes
Interrupting the immediate or delayed effects of gluten on the cells lining the intestine
Preventing the enzyme tTG from modifying gluten in the cell​, which helps to reduce an abnormal immune response
Inducing immune tolerance to protect against the effects of gluten by preventing an immune reaction
Interrupting the immune reactions that occur

Status

Active
Discontinued

Associated Websites

Drug Development Pipeline

Drug Development Pipeline

And to learn about the phases and process of drug development, download our Clinical Trials infographic.

Last updated July 7, 2020

Therapeutic Approach

Binding gluten so it’s not absorbed

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
BL-7010 (BioLineRx)

END PHASE TWO
Therapeutic Approach

Breaking down gluten using enzymes

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
IMGX-003/Latiglutenase (ImmunogenX)

MID PHASE TWO
TAK-062, or Kuma062 (Takeda Pharmaceuticals)

END PHASE ONE
Therapeutic Approach

Interrupting the immediate or delayed effects of gluten on the cells lining the intestine

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
Larazotide Acetate (9 Meters Biopharma)

START PHASE THREE
Therapeutic Approach

Preventing the enzyme tTG from modifying gluten in the cell​, which helps to reduce an abnormal immune response

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
GSK3915393 (GSK)

START PHASE ONE
ZED 1227 (Zedira and Dr. Falk)

MID PHASE TWO
Therapeutic Approach

Inducing immune tolerance to protect against the effects of gluten by preventing an immune reaction

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
TAK-101 ( Takeda Pharmaceuticals)

START PHASE TWO
Nexvax2 (ImmusanT)

START PHASE TWO
Name TBD (Selecta Biosciences)

MID PRE-CLINICAL
KAN-101 (Anokion)

START PHASE ONE
AG017 (ActoBio Therapeutics)

END PRE-CLINICAL
Therapeutic Approach

Interrupting the immune reactions that occur

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
PRV-015 (formerly AMG 714) Non-responsive celiac disease (Amgen/Provention Bio)

MID PHASE TWO
AMG 714 Refractory celiac disease type 2 (Amgen)

END PHASE TWO
CALY-002 (Calypso Biotech)

MID PRE-CLINICAL
Hu-Mik-Beta 1 Refractory celiac disease (National Cancer Institute, Mayo Clinic, University of Chicago Medicine Celiac Disease Center)

START PHASE ONE
Vedolizumab (Investigator initiated in collaboration with Takeda Pharmaceuticals)

END PHASE ONE
BNZ-2 (Bioniz Therapeutics)

END PRE-CLINICAL
No drugs match your filter selections.